The SDF1 antibody targets stromal cell-derived factor 1 (SDF1), also known as CXCL12. a chemokine critical in immune regulation, cell migration, and tissue homeostasis. SDF1 binds to the CXCR4 and CXCR7 receptors, activating signaling pathways involved in embryogenesis, angiogenesis, and inflammatory responses. It plays a key role in hematopoietic stem cell homing to bone marrow, neuronal development, and tumor metastasis by directing cell movement. Dysregulation of SDF1/CXCR4 signaling is linked to cancer progression, autoimmune diseases, and HIV infection, as CXCR4 serves as a co-receptor for viral entry.
SDF1 antibodies, including monoclonal and polyclonal variants, are widely used in research to detect SDF1 expression in tissues or biological fluids via techniques like ELISA, Western blot, and immunohistochemistry. Neutralizing antibodies block SDF1-CXCR4/CXCR7 interactions, offering therapeutic potential in inhibiting cancer metastasis, inflammatory disorders, or HIV replication. Some studies explore their use in stem cell therapies to enhance engraftment by modulating SDF1 gradients. Due to SDF1's structural isoforms (α, β, γ), antibody specificity is critical for accurate targeting. Ongoing research focuses on optimizing SDF1 antibody efficacy and specificity for clinical applications, including combination therapies and diagnostics.